View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 28, 2021

Northwell Health and CSHL open virtual Covid-19 drug trial

Northwell Health’s research arm Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory (CSHL) have initiated recruitment of participants in a fully virtual clinical trial of famotidine for treating adult covid-19 patients in the outpatient setting.

Northwell Health’s research arm Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory (CSHL) have initiated recruitment of participants in a fully virtual clinical trial of famotidine for treating adult covid-19 patients in the outpatient setting.

Sold over the counter as PEPCID, famotidine is a histamine 2 blocker to treat heartburn and assist with healing gastrointestinal ulcers.

This is the first time a fully virtual clinical trial was initiated by CSHL and Northwell Health. It has treated over 100,000 Covid-19 patients since the onset of the pandemic in March last year.

The in-home, randomised, double-blind, placebo-controlled trial will enrol Covid-19 patients across the greater New York area who are having mild to moderate symptoms and do not need hospitalisation.

Those enrolled in the study will get trained on how to use a cellular activated Apple iPad from their home, along with a Bluetooth-enabled scale, thermometer, fitness tracker, spirometer, thermometer and pulse oximeter.

The trial will analyse the safety and efficacy of famotidine in treating mild to moderate Covid-19.

In the trial, the patient will be prescribed oral famotidine 240mg or placebo to be taken daily for a maximum of 14 days.

This digital trial is intended to keep the participants completely out of the hospital throughout the treatment course.

CSHL assistant professor, Feinstein Institutes adjunct professor Tobias Janowitz said: “From the comfort of these patients’ own homes, we are taking the traditional clinical trial completely digital to study the efficacy and safety of a potential Covid-19 therapy.

“From assessment, to enrollment and daily data collection, we hope this study’s model will be an example for future clinical trials and will provide high quality data as we assess candidate treatments, like famotidine, to curb this disease.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU